Reactivity of antiglioma monoclonal antibodies for a large panel of cultured gliomas and other neuroectoderm derived tumors.
We produced three monoclonal antibodies, BF7, GE2 and CG12, against cultured human glioma cells. Their specificity was tested by an indirect antibody-binding radioimmunoassay on a panel of glial and non-glial tumor cell lines. BF7 and GE2 react preferentially with glioma cells and, except for one colon carcinoma line, they do not bind to the control non-neuroectodermal cells; they appear to be directed against common malignant glioma associated antigens. CG12, the third monoclonal antibody, binds to the great majority of tumor cell lines of neuroectodermal origin and does not bind to any other cell lines tested.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000912:Antibodies, Neoplasm / Q000276:immunology; D000918:Antibody Specificity; D001921:Brain / Q000276:immunology; D002460:Cell Line; D002478:Cells, Cultured; D003429:Cross Reactions; D004285:Dogs; D005910:Glioma / Q000276:immunology*; D006801:Humans; D008545:Melanoma / Q000276:immunology; D008579:Meningioma / Q000276:immunology; D009374:Neoplasms, Experimental / Q000276:immunology; D009447:Neuroblastoma / Q000276:immunology; D011817:Rabbits; D051381:Rats
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm